Association of primary tumor lymph node ratio with burden of liver metastases and survival in stage IV colorectal cancer

Ali Ahmad¹, Jeffrey Reha¹, Abdul Saied¹², N. Joseph Espat¹², Ponnandai Somasundar¹², Steven C. Katz¹²

¹Division of Surgical Oncology, Roger Williams Medical Center, Providence, RI 02908, USA; ²Department of Surgery, Boston University School of Medicine, Boston, MA, USA

Background: The primary objective of our study was to assess the association of primary tumor lymph node ratio (LNR) in stage IV colorectal adenocarcinomas (CRC) with overall survival (OS) and the extent of metastatic disease in the liver.

Methods: We analyzed data on 53 stage IV CRC patients who underwent surgical resection of the primary tumor. The median LNR of 0.25 was used to stratify patients into high LNR (H-LNR) and low LNR (L-LNR) groups. Statistical comparison was performed using chi square test and multiple regression models. OS was calculated using the Kaplan-Meier (KM) method while cox regression was used for multivariate analysis.

Results: H-LNR status was associated with the presence of >3 liver metastases (LM) [odds ratio (OR): 2.43, P=0.047] and bilobar LM (OR: 3.94, P=0.039). The OS in H-LNR patients was significantly worse in the entire cohort compared to L-LNR (9% vs. 34% at 3 years, P=0.027). The 5-year OS in patients undergoing liver resection for LM was also significantly worse in the H-LNR group (0% vs. 37%, P=0.013). LNR was independently associated with survival on multivariate analysis [HR: 2.63; 95% confidence intervals (CI), 1.13–6.14; P=0.025].

Conclusions: In stage IV CRC, LNR is associated with the extent of hepatic tumor burden and was an independent predictor of survival in patients undergoing liver resection.

Keywords: Colorectal cancer (CRC); liver metastases (LM); lymph node ratio (LNR); survival

Submitted May 30, 2016. Accepted for publication Jul 19, 2016.
doi: 10.21037/hbsn.2016.08.08
View this article at: http://dx.doi.org/10.21037/hbsn.2016.08.08

Introduction

Colorectal cancer (CRC) is the third most common cancer in the United States (1). The most important prognostic factor is the TNM stage and up to 60% of patients with CRC will develop metastases during the course of their disease (2). Outcomes in these patients depend heavily on the nature and extent of distant metastases (3). The significance of primary tumor characteristics, such as lymph node (LN) status on survival in patients with Stage II/III CRC is well established (4,5). The implications of primary tumor draining LN burden are considered less pivotal in the setting of stage IV disease.

National guidelines recommend evaluation of at least 12 LNs for adequate staging in CRC (6). The extent of nodal involvement is a well established prognostic factor in patients with non-metastatic CRC (4,5,7). In addition to conventional LN status, several authors have proposed surrogate methods of nodal assessment for more accurate
staging (8,9). Of those, a valuable tool is the lymph node ratio (LNR), defined as the ratio of positive LNs to the total number of nodes harvested. Recently, the significance of LNR has been explored for various neoplasms including CRC. Although some authors have suggested a role for LNR in stage IV CRC (9,10), the relative dearth of such evidence limits its utility in planning multimodality management of these patients.

The majority of patients with stage IV CRC have liver dominant metastatic disease. Outcomes in such patients are defined by the extent of hepatic tumor burden (3,11). Although aggressive primary tumor characteristics portend a high risk for distant metastases (10,11), the correlation between primary tumor biology and the extent of intrahepatic metastatic disease requires further clarification. The biologic significance of nodal staging in patients with liver metastases (LM) may become increasingly important as patients with synchronous disease are more likely to obtain control of their liver disease with more effective systemic regimens and potentially immunotherapy (12). As such, patients who present with synchronous LM are likely to undergo primary tumor resection at some point during the course of their disease (13).

The objective of our study was to assess the impact of primary tumor LNR in stage IV CRC on survival and its association with the extent of hepatic tumor burden. Such associations would confirm the importance of rigorous nodal staging during resection of the primary tumor in patients with disseminated disease. We hypothesized that high primary tumor LNR is associated with more extensive hepatic metastases and worse survival outcomes in stage IV CRC patients. To our knowledge, an association between primary tumor LNR and intrahepatic tumor burden has not been previously reported.

**Methods**

With approval of the Institutional Review Board and in accordance with Health Insurance Portability and Accountability Act regulations, a prospectively maintained Roger Williams Cancer Center tumor database was used. Between 2004 and 2011, 79 patients with stage IV CRC were treated at our institution. We excluded 26 patients who did not undergo resection of the primary tumor. Retrospective chart review was then performed on the remaining 53 patients that met final inclusion criteria. Variables examined included age, gender, primary tumor site, LN status, burden of hepatic metastases, carcinoembryonic antigen (CEA) level, presence of extrahepatic metastases and surgical intervention.

Odds ratio (OR) calculations were used for quantitative assessment of associations and statistical analysis was derived using the chi-square test. A multiple regression model was utilized to determine multivariate statistical independence on factors that were found to be significant on univariate comparison. LNR was defined as the ratio of primary tumor LN with metastatic carcinoma to the total number of LN retrieved. With the assumption of a normal distribution of data, all the associated variables were tested on a correlation matrix using the Pearson product-moment correlation test. Correlation coefficient was calculated by linear regression. LNR cut-off values were analyzed for predictability using receiver operating characteristic (ROC) curves. Survival curves were generated using the Kaplan-Meier (KM) method and statistical comparison was done using the log-rank test. The cox regression model was used for multivariate survival analysis. All statistical analyses report 95% confidence intervals (CI) and were performed using SPSS for windows (SPSS Inc, Chicago, IL, USA). Significance of difference was assumed at P<0.05.

The decision and timing of surgical resection of primary tumor and LM was based on clinical assessment by a surgical oncologist in conjunction with a multidisciplinary team. Extent and nature of hepatic surgery was similarly individualized for each patient based on rigorous clinicopathologic evaluation. Patients were selected for hepatic resection when complete tumor clearance was possible along with an anticipated adequate liver remnant.

**Results**

The median number of LNs retrieved was 17 (range, 2–39). Thirty-nine patients (74%) had ≥12 LNs retrieved, consistent with national guidelines. Median follow up was 16 months (range, 0–117 months). The median LNR was 0.25 (range, 0–0.94) and used a cutoff to define patients with a low LNR (L-LNR, ≤0.25) or high LNR (H-LNR, >0.25), as previously reported (8). Among 53 eligible patients, 26 (49%) had H-LNR. Demographic and tumor characteristics with respect to LNR status are outlined in Table 1.

Age and gender were fairly well distributed within both groups. Most primary tumors were of colonic origin (72%), while the remaining were rectal adenocarcinomas. The median CEA level was 16.5 ng/mL (range, 0.5–2,725 ng/mL). This value was used as a cutoff for comparative analysis. Among all patients, 51% had >3 LM,
51% had bilobar hepatic involvement and 45% had a hepatic metastasis >5 cm. Sixteen patients (30%) had extrahepatic metastases, with lung being the most common site of disease outside the liver. Fourteen patients with extrahepatic metastases (n=16, 88%) did not undergo any hepatic surgery. All patients received chemotherapy either in the neo-adjuvant or adjuvant setting. The dose and timing of chemotherapy was individualized to each patient after a multidisciplinary discussion. Fifteen patients with rectal cancer (n=15, 100%) and 12 patients with colon cancer (n=38, 32%) received neo-adjuvant chemotherapy prior to resection of the primary tumor.

**LNR analysis**

We did not identify an association between age, gender, primary tumor site or CEA level with LNR (*Table 2*). We found that H-LNR was associated with the presence of >3 LM (OR: 3.21; 95% CI, 1.04–9.88; P=0.042) and bilobar LM (OR: 4.50; 95% CI, 1.41–14.28; P=0.011). Size >5 cm or the presence of extra-hepatic disease were not significant correlates of LNR. Patients with H-LNR were significantly less likely to undergo surgical resection of LM (OR: 0.25; 95% CI, 0.07–0.81; P=0.021). On multiple regression analysis (*Table 2*), factors independently associated with LNR included the presence of >3 LM (OR: 2.43; 95% CI, 1.12–8.85; P=0.047) and bilobar disease (OR: 3.94, 95% CI, 1.07–14.49; P=0.039). Surgical intervention for metastatic disease was negatively correlated with H-LNR however it was not statistically significant (*Table 3*).

ROC curves were derived to analyze the predictive value of LNR on liver tumor burden and survival (*Figure 1*). A cutoff of 0.25 was found to be the most predictive for the presence of >3 LM (sensitivity 63%, specificity 65%), bilobar hepatic metastases (sensitivity 65%, specificity 67%) and overall survival (OS) (sensitivity 63%, specificity 72%). Lower LNR cutoffs increased the sensitivity but decreased the specificity of this parameter and the reverse was noted for higher cutoffs.

**Survival analysis**

In our group of patients with colorectal LM, with data assumed to be normally distributed, increasing LNR was correlated with worse OS. On linear regression, each increase of LNR value by 0.1 was associated with a decrease in OS by 3.1 months (*Figure 2*, P=0.009). The median OS for patients with H-LNR was 14 months as compared to 26 months for those with L-LNR (*Figure 3*). The 3-year OS for H-LNR group was also significantly worse than the L-LNR group (9% vs. 34%, P=0.027). On multivariate analysis of the entire cohort (*Table 4*), factors independently associated with worse OS included age ≥65 years (HR: 2.33; 95% CI, 1.16–4.82; P=0.022), H-LNR (HR: 2.63; 95% CI, 1.13–6.14; P=0.025), presence of >3 LM (HR: 2.05; 95% CI, 1.13–3.69; P=0.018).
Table 2 Univariate and multivariate analysis of factors associated with LNR

<table>
<thead>
<tr>
<th>Variable</th>
<th>Univariate comparison</th>
<th></th>
<th>Multivariate comparison</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>95% CI</td>
<td>P value</td>
<td>OR</td>
</tr>
<tr>
<td>Age ≥65 years</td>
<td>0.86</td>
<td>0.29–2.55</td>
<td>0.781</td>
<td></td>
</tr>
<tr>
<td>Gender: male vs. female</td>
<td>0.85</td>
<td>0.28–2.56</td>
<td>0.778</td>
<td></td>
</tr>
<tr>
<td>Primary: colon vs. rectum</td>
<td>0.54</td>
<td>0.16–1.82</td>
<td>0.319</td>
<td></td>
</tr>
<tr>
<td>&gt;3 liver metastases</td>
<td>3.21</td>
<td>1.04–9.88</td>
<td>0.042</td>
<td>2.43</td>
</tr>
<tr>
<td>Bilobar hepatic metastases</td>
<td>4.50</td>
<td>1.41–14.28</td>
<td>0.011</td>
<td>3.94</td>
</tr>
<tr>
<td>Size of largest liver lesion &gt;5 cm</td>
<td>0.68</td>
<td>0.18–2.49</td>
<td>0.561</td>
<td></td>
</tr>
<tr>
<td>Extra-hepatic metastases</td>
<td>1.26</td>
<td>0.39–3.99</td>
<td>0.697</td>
<td></td>
</tr>
<tr>
<td>CEA level &gt;16.5 ng/mL</td>
<td>1.36</td>
<td>0.45–4.07</td>
<td>0.578</td>
<td></td>
</tr>
<tr>
<td>Liver surgery</td>
<td>0.25</td>
<td>0.07–0.81</td>
<td>0.021</td>
<td>0.71</td>
</tr>
</tbody>
</table>

LNR, lymph node ratio; OR, odds ratio; CI, confidence interval; CEA, carcinoembryonic antigen.

Table 3 Pearson correlation matrix of the factors associated with LNR

<table>
<thead>
<tr>
<th>Variable</th>
<th>High LNR</th>
<th>&gt;3 LM</th>
<th>Bilobar LM</th>
<th>&gt;5 cm</th>
<th>EHD</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt;3 LM</td>
<td>+0.396*</td>
<td>+0.412*</td>
<td>+0.887</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bilobar LM</td>
<td>+0.412*</td>
<td>+0.887</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;5 cm</td>
<td>−0.039</td>
<td>−0.079</td>
<td>−0.101</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EHD</td>
<td>+0.024</td>
<td>+0.053</td>
<td>+0.108</td>
<td>−0.082</td>
<td></td>
</tr>
<tr>
<td>Liver resection</td>
<td>−0.230</td>
<td>−0.404</td>
<td>−0.452</td>
<td>−0.044</td>
<td>−0.216</td>
</tr>
</tbody>
</table>

*, P<0.05; +, positive correlation; −, negative correlation. LNR, lymph node ratio; LM, liver metastases; EHD, extra-hepatic disease.

Figure 1 ROC analysis of factors associated with LNR. Dotted lines at point of intersection represent sensitivity and specificity of LNR =0.25. ROC, receiver operating characteristic; LNR, lymph node ratio.
CI, 1.13–5.28; P=0.028), and bilobar hepatic metastases (HR: 2.81; 95% CI, 1.25–6.29; P=0.012).

LNR was also associated with worse OS in patients who underwent resection of LM (Figure 4). In these patients, the median OS in H-LNR group was significantly worse than the low LNR group (13 vs. 27 months, P=0.013). The 5-year OS for patients with L-LNR was 37% while none of the patients in the H-LNR group were alive at 5 years following resection of LM. Seven patients in the H-LNR group (27%) and 4 patients in the L-LNR group (15%) had high risk features defined as the presence of bilobar hepatic metastases, >3 LM along with the presence of extra-hepatic disease. The median survival of H-LNR patients with high risk features was 11 months compared to 21 months for those L-LNR group with high risk features (P=0.029).

Discussion
The management of patients with stage IV CRC has evolved considerably over the past decade. Advances in multimodal
care have led to improved survival outcomes (14). Although LN status serves as a strong prognostic determinant in CRC patients without distant metastases, the significance of primary tumor LNR is not well understood in the context of stage IV disease. Outcomes in such patients are largely defined by the extent and nature of hematoogenous metastatic disease (13). We have demonstrated that primary tumor LNR predicted long-term survival following resection of LM and served as an independent predictor of intrahepatic tumor burden.

Currently, national guidelines recommend retrieval of at least 12 LN for appropriate staging in CRC (6). Nodal stage is determined by the number of positive nodes in the current TNM staging system (AJCC 7th edition), as opposed to LNR. Adequate lymphadenectomy enables appropriate staging of patients, which greatly facilitates management decisions in patients with CRC (15). Although adequate nodal staging should be attempted in all patients, a variety of factors can influence the number of LN ultimately retrieved. Appropriate surgical technique along with diligent pathologic examination of resected specimen are required to consistently attain that goal (16,17). Due to variability in surgical technique and pathologic assessment of specimens, recent studies have proposed alternative LN parameters which may be more reliable than standard nodal staging in predicting outcomes (8,9). The most thoroughly investigated alternative nodal staging approach is LNR (18,19).

The prognostic significance of LNR has been well established for several solid organ malignancies (20,21), including CRC (22). Few studies have evaluated the role of LNR in stage IV CRC. Derwinger and Gustavsson (10) reported worse survival outcomes with increasing LNR in patients with stage IV CRC. However, in that study, the median number of nodes assessed was 10, whereas it is 17 in our present report. Furthermore, the authors did not correlate LNR with extent of intrahepatic metastatic disease. Ozawa et al. (23) recently reported a relationship between LNR and survival in patients with metastatic CRC. In our patients, the median survival of stage IV CRC patients was 26 months in the L-LNR group and 14 months in the H-LNR group. Similarly, for patients with high risk features or those who had undergone surgical intervention for CRLM, the 5-year OS was significantly better in the L-LNR group. Vaccaro et al. (24) showed that LNR >0.25 was an independent prognostic factor for overall and cancer specific survival in patients with non-metastatic CRC. Several other LNR cutoffs have been proposed based on quartiles, means and various other statistical derivations without any reliable consensus (25,26). We used the median LNR as the cutoff as reported by Ozawa and colleagues (23). On ROC analysis, this cutoff value was found to be the most accurate in predicting hepatic tumor burden and survival in our patients. Importantly, we confirmed in our study group that LNR correlated with survival time in a continuous manner, indicating that our results were not dependent on a particular LNR value.

The majority of patients with stage IV CRC present with liver-only or liver-dominant metastatic disease. All of the patients included in our study had LM and 30% had extra-hepatic disease as well. Surgical resection of CRC LM is the preferred approach (27,28) but unfortunately many patients who are diagnosed with metastatic disease are found to be unresectable at the time of initial evaluation (29). Pathological characteristics of the primary tumor, including LNR, predict the extent of metastatic disease and may assist in identifying high risk patients. In our study, LNR was associated with the presence of more than 3 LM and bilobar disease. Both of these factors weigh heavily when a patient is considered for liver surgery (30). This association may be used to identify patients undergoing liver surgery who are at high risk for recurrence and potentially benefit from neoadjuvant therapy or require more intensive surveillance.

Due to the retrospective design, the exact influence of specific confounding variables could not be quantified. We speculate that the longevity in survival seen in patients with low LNR was influenced by favorable tumor biology in general. While adjuvant therapy likely impacted the outcome of patients in our study, our small sample size did not allow us to examine this in stratified fashion. However, the association of survival with LNR remained significant on multivariate model. Due to improvements in multimodality care, patients with LM from CRC are experiencing prolonged periods of disease control. Primary tumor biologic surrogates, such as LNR, may acquire increased relevance in patients with LM who survive for extended periods of time.

Conclusions

With the development of novel therapeutic options, patients with stage IV CRC have improved outcomes. Risk stratification of these patients may further assist in improvement of care and potentially open avenues for further progress. Considering LNR for patients with
metastatic CRC who have undergone surgical resection of the primary tumor should be considered a routine parameter in the evaluation of these patients. Our study defines the potential utility of LNR in predicting hepatic tumor burden and survival, which may influence the complex decisions surrounding multimodality management of patients with stage IV CRC. We believe that even in the setting of stage IV disease, if resection of the primary tumor is required, principles of appropriate nodal staging should be practiced.

Acknowledgements

We would like to acknowledge the contribution of Cheryl Raffel, cancer tumor registrar, for assisting in data acquisition.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The study was approved by institutional ethics board of Roger Williams Medical Center (No. 00000088888) and written informed consent was obtained from all patients.

References


Cite this article as: Ahmad A, Reha J, Saied A, Espat NJ, Somasundar P, Katz SC. Association of primary tumor lymph node ratio with burden of liver metastases and survival in stage IV colorectal cancer. HepatoBiliary Surg Nutr 2017;6:154-161. doi: 10.21037/hbsn.2016.08.08